ArticleJACC. Case reports2026
Coexistence of Hypertrophic Cardiomyopathy and Hereditary Transthyretin Amyloid Cardiomyopathy.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeft ventricular wall thickening may result from disease such as hypertrophic cardiomyopathy (HCM) or infiltrative cardiomyopathies such as transthyretin amyloidosis (ATTR). When features of both conditions coexist, distinguishing the dominant pathology can be challenging and may influence management. CASE SUMMARY: A 72-year-old man presented with progressive exertional dyspnea and syncope. He was found to have severe left ventricular outflow tract obstruction with systolic anterior motion of the mitral valve. He experienced marked symptomatic improvement after initiation of mavacamten for presumed HCM. Genetic testing later revealed a pathogenic TTR p.Val50Met variant, and technetium-99m pyrophosphate scintigraphy demonstrated grade 3 myocardial uptake consistent with hereditary ATTR cardiomyopathy. Persistent symptoms led to septal myectomy, which demonstrated marked myocyte hypertrophy and moderate myocardial amyloid deposition but insufficient infiltration to explain the hypertrophy. DISCUSSION: This case highlights the diagnostic complexity of coexisting HCM and hereditary ATTR cardiomyopathy and underscores the importance of multimodality imaging, genetic testing, and pathologic correlation. TAKE-HOME MESSAGES: Dynamic left ventricular outflow tract obstruction does not exclude cardiac amyloidosis. Dual cardiomyopathies should be considered when clinical, imaging, and genetic findings appear discordant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.